In this study, we evaluated the therapeutic potential of the Ab27 chimeric monoclonal antibody against liver and colon cancer cells expressing endogenous levels of TM4SF5 or stably overexpressing the protein in vitro and in vivo. This evidence concerns the gene TM4SF5 and malignant colon neoplasm.